Cristel V. Camacho

This study investigates PARP16's role in ovarian cancer by showing that inhibiting it with DB008 disrupts ribosome MARylation, impairs protein homeostasis, and reduces tumor growth.

The paper maps PARP1 ADP-ribosylated proteomes in breast cancer subtypes, identifying subtype-specific modifications and their functional implications.

The paper examines the molecular effects of varying estradiol doses on estrogen receptor enhancers in breast cancer cells, finding distinct biological outcomes at low versus high doses.

This study identifies and characterizes 17 high frequency oncohistone mutations in breast cancer that promote cancer-related phenotypes and may act as potential cancer drivers.

This study identifies PARP7 as a key regulator of C/EBPβ-dependent adipogenesis and shows it senses nuclear NAD+ levels to control gene expression and lipid production in mammary glands.

This study identifies XCP, a protein from the lncRNA1456, which interacts with PHF8 to regulate gene expression and cancer pathways in breast cancer.

This study shows that relaxin reduces estrogen receptor alpha phosphorylation and alters estrogen-dependent gene expression in myometrial cells.

This study shows that RBN-2397, a PARP7 inhibitor, reduces ovarian cancer cell proliferation and migration, and synergizes with paclitaxel to enhance these effects.

The paper develops and characterizes new recombinant ADP-ribose binding reagents that enable species-specific detection of mono and poly ADP-ribose in antibody-based assays.

The paper develops and characterizes PAR-Trackers, new tools for detecting poly(ADP-ribose) in vitro and in vivo, showing improved sensitivity and spatial-temporal resolution.